The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-11 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Conversely, of the 251 known stable nuclides, only five have both an odd number of protons and odd number of neutrons: hydrogen-2 (deuterium), lithium-6, boron-10, nitrogen-14, and tantalum-180m. Also, only four naturally occurring, radioactive odd–odd nuclides have a half-life >109 years: potassium-40, vanadium-50, lanthanum-138, and lutetium-176. Odd–odd primordial nuclides are rare because most odd–odd nuclei beta-decay, because the decay products are even–even, and are therefore more strongly bound, due to nuclear pairing effects. Yet another effect of the instability of an odd number of either type of nucleon is that odd-numbered elements tend to have fewer stable isotopes. Of the 26 monoisotopic elements (those with only one stable isotope), all but one have an odd atomic number, and all but one has an even number of neutrons: the single exception to both rules is beryllium. The end of the stable elements occurs after lead, largely because nuclei with 128 neutrons—two neutrons above the magic number 126—are extraordinarily unstable and almost immediately alpha-decay. This contributes to the very short half-lives of astatine, radon, and francium. A similar phenomenon occurs to a much lesser extent with 84 neutrons—two neutrons above the magic number 82—where various isotopes of lanthanide elements alpha-decay.
The first long-acting analogue, insulin glargine, was approved in 2000. Insulin aspart, insulin glulisine, and insulin detemir were all approved by 2005. The second wave of insulin analogues, which include insulin degludec and insulin icodec, started in the 2010s. Insulin analogues are on the World Health Organization's List of Essential Medicines.
==== United States ==== Phenylethylamine is not a scheduled substance in the United States. However, at least one person in the United States has been prosecuted under the Federal Analogue Act for selling phenylethylamine with the prosecutions argument that PEA is a structural analog of amphetamine and methamphetamine.
The design process at Ilyushin was managed by Sergey Ilyushin's successor as head of the bureau, Genrikh Novozhilov. The timescale announced in 1973 envisaged first flight in 1976 and service entry in time for the Moscow Olympics in 1980. The prototype flew at Khodynka airfield (where Ilyushin's experimental factory was) on December 22, 1976 (Soviet airliners often flew before the close of calendar years to meet the requirements of five-year plans). It was announced that the type had a patented electromagnetic pulse deicing system. which used 500 times less energy than conventional deicers. It is claimed that over 50 new technological processes were introduced into Soviet practice as a result of the Il-86 programme. The initial test programme was flown by Ilyushin staff, ending two months ahead of schedule on October 20, 1978. Other sources claim that these tests were completed on 22 September 1978. (According to a faster schedule announced at the time of the first flight, Ilyushin tests were to have ended in time for the 60th anniversary of the October Revolution on November 7, 1977.) In-house testing involved speeds up to Mach 0.93 and bank angles up to 11 degrees greater than specified. Initial certification flying by pilots independent of Ilyushin ended on June 6, 1977. State acceptance trials began on April 24, 1979, and ended on December 24, 1980. Certification by Gosaviaregistr SSSR [the USSR State Aviation Registry] was granted under certificate number 10–86. The Il-86 entered Aeroflot service on 26 December the same year.
== Human uses == Human uses of AGPs include the use of Gum arabic in the food and pharmaceutical industries because of natural properties in thickening and emulsification. AGPs in cereal grains have potential applications in biofortification, as sources of dietary fibre to support gut bacteria and protective agents against ethanol toxicity.
Sources: en.wikipedia.org
Per- and polyfluoroalkyl substances (PFAS or PFASs) are a group of synthetic organofluorine chemical compounds that have multiple fluorine atoms attached to an alkyl chain. Because of their high chemical and thermal stability, these compounds have long environmental lifetimes, and thus are commonly called "forever chemicals". The first PFAS, polychlorotrifluoroethylene, was synthesized in 1934. Their widespread use began in 1938 with the invention of Teflon (polytetrafluoroethylene), a fluoropolymer coating that resists heat, oil, stains, grease, and water. Since their inception, thousands of PFAS compounds have been created. They are used in a wide variety of products including waterproof fabric, yoga pants, carpets, shampoo, mobile phone screens, wall paint, furniture, adhesives, food packaging, firefighting foam, electrical insulation, and cosmetics. PFAS are often found in groundwater, wastewater and soil; wastewater treatment facilities and landfills have the highest levels of pollution. Furthermore, crop uptake of PFAS and bioaccumulation of PFAS into fish, livestock, and wildlife can act as potential routes of human exposure. In addition, areas near airports and air force bases are contaminated from the use of PFAS-containing firefighting foam.
=== RsfS === RsfS (Ribosome silencing factor S) inhibits translation by preventing the 30S and 50S subunits of the ribosome from binding to each other again after they split during ribosome recycling. It has also been suggested to be a ribosome biogenesis factor rather than a hibernation factor.
== Cost == VESA, the creators of the DisplayPort standard, state that the standard is royalty-free to implement. However, in March 2015, MPEG LA issued a press release stating that a royalty rate of $0.20 per unit applies to DisplayPort products manufactured or sold in countries that are covered by one or more of the patents in the MPEG LA license pool, which includes patents from Hitachi Maxell, Philips, Lattice Semiconductor, Rambus, and Sony. In response, VESA updated its DisplayPort FAQ page in November 2015 with the following statement:
=== Che–Cl === Zhijian James Chen (b. 1966). Chinese-American biochemist at the University of Texas Southwestern Medical Center, known discovering mechanisms by which nucleic acids trigger innate and autoimmune responses from the interior of a cell. Member Natl. Acad. Sci. USA. Albert Chibnall FRS (1894–1988), British biochemist known for his work on the nitrogen metabolism of plants. Ruth Chiquet-Ehrismann (1954–2015), Swiss biochemist and cell biologist working on interactions in the extracellular matrix. Cyrus Chothia FRS (1942–2019). British biochemist at Cambridge known for work on protein structure. Gilbert Chu (b. 1946). American biochemist at Stanford, known for investigating how cells react to DNA damage from radiation. George M. Church (b. 1954). American geneticist at Harvard and MIT, known for pioneering personal genomics and synthetic biology. Member Natl. Acad. Sci. USA. Aaron Ciechanover (b. 1947). Israeli biochemist at the Technion, Haifa, known for work on protein turnover. Nobel Prize for Chemistry in 2004. Foreign associate Natl. Acad. Sci. USA. Vintilă Ciocâlteu (1890–1947) Roumanian physician, biochemist, researcher, professor, and author. Hans Thacher Clarke (1887–1972), British-born American biochemist at Columbia University, known for the Eschweiler–Clarke reaction. Member Natl. Acad. Sci. USA. Jane Clarke (b. 1950). Biochemist at Cambridge known for work on folding and assembly of proteins. Steven Clarke (b. 1949). American biochemist at UCLA, known for work on molecular damage and molecular repair mechanisms. Roy Elwood Clausen (1891–1956).
=== Luminous flux: watt equivalent === With the phaseout of the incandescent lamp in the United States and European Union in the early 21st century, manufacturers and sellers of more energy-efficient lamps have compared the visible light output of their lamps to commonly used incandescent lamp sizes with the watt equivalent or watt incandescent replacement (usually with a lowercase w as a unit symbol, as opposed to capital W for the actual wattage). 1 watt incandescent replacement corresponds to 15 lumens. Thus, a 72-watt halogen lamp, a 23-watt compact fluorescent lamp and a 14-watt light-emitting diode lamp, all of which emit 1500 lumens of visible light, are all marketed as "100 watt incandescent replacement" (100w).
Sources: en.wikipedia.org
The microgravity environment allows control of convection in liquids or gasses, and the elimination of sedimentation. Diffusion becomes the primary means of material mixing, allowing otherwise immiscible materials to be intermixed. The environment allows enhanced growth of larger, higher-quality crystals in solution. The ultraclean vacuum of space allows the creation of very pure materials and objects. The use of vapor deposition can be used to build up materials layer by layer, free from defects. Surface tension causes liquids in microgravity to form perfectly round spheres. This can cause problems when trying to pump liquids through a conduit, but it is very useful when perfect spheres of consistent size are needed for an application. Space can provide readily available extremes of heat and cold. Sunlight can be focused to concentrate enough heat to melt the materials, while objects kept in perpetual shade are exposed to temperatures close to absolute zero. The temperature gradient can be exploited to produce strong, glassy materials.
April 8: Decree protecting wives of political emigrants, but not husbands of female emigrants. August 31: Decree adjusting penalties for pregnant women sentenced to the pillory. September 20: Law on civil status registration and divorce, establishing near equality between spouses. Minimum marriage age set at 13 for girls and 15 for boys. 1793
== Names of the proposed state == In the August 1991 draft of the treaty, the proclaimed name for the new country was the Union of Soviet Sovereign Republics (Russian: Союз Советских Суверенных Республик, romanized: Soyuz Sovetskikh Suverennykh Respublik). This would conserve the Russian "СССР" acronym, meaning "USSR" and "Soviet Union" in English and other languages. By September 1991, support for continuing the Soviet system had transitioned into reforming the Soviet Union into a confederation of sovereign states. The final draft renamed the proposed state as the Union of Sovereign States (Russian: Союз Суверенных Государств, romanized: Soyuz Suverennykh Gosudarstv).
== Conferences == In May 2010, the Foundation sponsored a conference on "Creatine in Health, Medicine and Sport", held at Downing College, Cambridge. This was followed by the first Macular Carotenoids Conference also held at Downing College in July 2011 which led to a book, Carotenoids and Retinal Disease. Further conferences on Macular Carotenoids at Downing College were held in 2013 and 2015. The BON (Brain and Ocular Nutrition) Conference is to be held 11–13 July 2018 again at Downing College, Cambridge.
==== Multiple products ==== In all of the above examples, the initial nuclide decays into just one product. Consider the case of one initial nuclide that can decay into either of two products, that is A → B and A → C in parallel. For example, in a sample of potassium-40, 89.3% of the nuclei decay to calcium-40 and 10.7% to argon-40. We have for all time t:
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.